What is Leerink Partnrs' Forecast for Nuvalent Q2 Earnings?

Nuvalent, Inc. (NASDAQ:NUVL - Free Report) - Analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for shares of Nuvalent in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will earn ($1.17) per share for the quarter. The consensus estimate for Nuvalent's current full-year earnings is ($3.86) per share. Leerink Partnrs also issued estimates for Nuvalent's Q3 2025 earnings at ($1.18) EPS and Q4 2025 earnings at ($1.10) EPS.

A number of other research firms also recently commented on NUVL. HC Wainwright reiterated a "buy" rating and issued a $110.00 price objective on shares of Nuvalent in a report on Friday, January 17th. UBS Group assumed coverage on shares of Nuvalent in a report on Thursday, October 24th. They issued a "neutral" rating and a $100.00 price objective for the company. Wedbush reiterated an "outperform" rating and issued a $115.00 price objective on shares of Nuvalent in a report on Monday, January 13th. Finally, BMO Capital Markets raised their price target on shares of Nuvalent from $132.00 to $134.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Nuvalent currently has a consensus rating of "Moderate Buy" and a consensus target price of $112.36.

Nuvalent Trading Down 0.5 %

NUVL stock traded down $0.44 during mid-day trading on Friday, reaching $82.90. The company's stock had a trading volume of 323,571 shares, compared to its average volume of 489,410. The stock has a market cap of $5.89 billion, a PE ratio of -23.89 and a beta of 1.38. Nuvalent has a fifty-two week low of $61.79 and a fifty-two week high of $113.51. The company's 50 day moving average is $83.26 and its two-hundred day moving average is $88.03.

Nuvalent (NASDAQ:NUVL - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.35). During the same period in the previous year, the business posted ($0.59) EPS.

Hedge Funds Weigh In On Nuvalent

Several large investors have recently bought and sold shares of NUVL. Crowley Wealth Management Inc. acquired a new stake in Nuvalent during the 4th quarter worth $27,000. Vanguard Group Inc. boosted its stake in Nuvalent by 8.9% during the 4th quarter. Vanguard Group Inc. now owns 4,499,864 shares of the company's stock worth $352,249,000 after purchasing an additional 366,239 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in Nuvalent during the 4th quarter worth $595,000. American Century Companies Inc. acquired a new stake in Nuvalent during the 4th quarter worth $14,590,000. Finally, Teacher Retirement System of Texas boosted its stake in Nuvalent by 43.1% during the 4th quarter. Teacher Retirement System of Texas now owns 10,609 shares of the company's stock worth $830,000 after purchasing an additional 3,197 shares during the period. Institutional investors and hedge funds own 97.26% of the company's stock.

Insider Buying and Selling

In other news, CEO James Richard Porter sold 27,000 shares of Nuvalent stock in a transaction on Monday, December 16th. The shares were sold at an average price of $86.61, for a total transaction of $2,338,470.00. Following the completion of the sale, the chief executive officer now directly owns 188,113 shares of the company's stock, valued at approximately $16,292,466.93. The trade was a 12.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Henry E. Pelish sold 2,483 shares of Nuvalent stock in a transaction on Monday, January 6th. The stock was sold at an average price of $79.68, for a total transaction of $197,845.44. Following the sale, the insider now directly owns 59,981 shares of the company's stock, valued at approximately $4,779,286.08. This trade represents a 3.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 83,800 shares of company stock valued at $6,812,164. Company insiders own 12.52% of the company's stock.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.